Diseases [C] » Digestive System Diseases [C06] » Liver Diseases » Hepatitis » Hepatitis, Chronic
Diseases [C] » Pathological Conditions, Signs and Symptoms [C23] » Pathologic Processes » Disease Attributes » Chronic Disease » Hepatitis, Chronic
Description
INFLAMMATION of the LIVER with ongoing hepatocellular injury for 6 months or more, characterized by NECROSIS of HEPATOCYTES and inflammatory cell (LEUKOCYTES) infiltration. Chronic hepatitis can be caused by viruses, medications, autoimmune diseases, and other unknown factors. MeSH
Hierarchy View
Subtype Terms (4)
Hepatitis, Autoimmune
24 drugs (15 approved, 9 experimental)
Hepatitis B, Chronic
165 drugs (46 approved, 119 experimental)
Hepatitis C, Chronic
241 drugs (103 approved, 138 experimental)
Hepatitis D, Chronic
14 drugs (9 approved, 5 experimental)
Phase 3 Indicated Drugs (3)
Phase 2 Indicated Drugs (4)
Phase 1 Indicated Drugs (5)
Other Experimental Indicated Drugs (1)
Organization Involved with Phase 4 Indications (145)
Center For Hepatitis C, Atlanta, GA
Chinese University of Hong Kong
Chronic Liver Disease Foundation
Dalin Tzu Chi General Hospital
First People's Hospital of Foshan
Gottfried Wilhelm Leibniz Universität Hannover
Hannover Clinical Trial Center GmbH
Hospital Universitario Fundación Alcorcón
Huazhong University of Science and Technology
Huizhou People's Central Hospital
Humanity & Health Research Centre
International Society for Infectious Diseases
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Nanyang Technological University
National Cheng Kung University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institutes of Health (NIH)
National University of Singapore
People's Liberation Army of China
Qingdao Infectious Diseases Hospital
Shenzhen Third People's Hospital
Shineway Pharmaceutical Co.,Ltd
Taichung Veterans General Hospital
Taipei Veteran General hospital
The Fifth People's Hospital of Suzhou
The Third Hospital of Qinhuangdao City
The Third People's Hospital of Taiyuan
Tung's Taiching MetroHarbor Hospital
University of Modena and Reggio Emilia
Organization Involved with Phase 3 Indications (91)
Ascletis Pharmaceuticals Co., Ltd.
Azienda Ospedaliera Antonio Cardarelli
Azienda Ospedaliera San Camillo Forlanini
Azienda Ospedaliera S Giovanni Battista
Azienda Ospedaliera V. Cervello
Bangabandhu Sheikh Mujib Medical University
Beijing Kawin Technology Share-Holding Co., Ltd.
Casa Sollievo della Sofferenza IRCCS
Federal University of Rio Grande do Sul
French National Agency for Research on AIDS and Viral Hepatitis
National Hepatology & Tropical Medicine Research Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Ospedale Civile Vittorio Emanuele II, Bisceglie
Ospedale R. Dimiccoli, Barletta
Ospedale Santa Caterina Novella, Galatina
Organization Involved with Phase 2 Indications (100)
Australian Respiratory and Sleep Medicine Institute
Beijing Clinical Service Center
Fundacion de Investgacion de Diego
Guangzhou Baidi Biotechnology Co., Ltd
Guangzhou Pharmaceucal Company Limited
Mashhad University of Medical Sciences
Moscow Regional Resarch adn Clinical Institute
National Center for Complementary and Integrative Health (NCCIH)
Razi Vaccine and Serum Research Institute
Second People's Hospital of Yunnan Province
Shanghai Sundise Traditional Chinese Medicine Co., Ltd.
Southern California Research Center
Spring Bank Pharmaceuticals, Inc.
Organization Involved with Phase 1 Indications (31)
Organization Involved with Other Experimental Indications (23)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.